Moderna, Merck claim melanoma vaccine halves recurrence risk in Phase III trial

Moderna, Merck claim melanoma vaccine halves recurrence risk in Phase III trial

商业 健康
登录后即可置顶此事件

Moderna and Merck said their personalized mRNA melanoma vaccine, intismeran autogene, cut the risk of disease recurrence or spread in a Phase III trial of 1,137 high-risk patients, with the results unveiled at the American Society of Clinical Oncology meeting in Chicago on August 17. Earlier reports from Gizmodo and Ars Technica noted that the vaccine, given alongside Merck’s Keytruda, extended recurrence-free and distant metastasis-free survival. Yahoo Finance later observed that Moderna’s shares fell 12% in pre-market trading after a prior 177% surge on the same trial success.

参与者

Moderna Merck Stéphane Bancel

地点

American Society of Clinical Oncology meeting

文章

2026年八月24日
1 篇总计
Inside Moderna and Merck’s cancer vaccine triumph
Inside Moderna and Merck’s cancer vaccine triumph

STAT • 08月24日 08:35

A phase III study of the mRNA-based melanoma vaccine intismeran autogene showed a statistically significant reduction in the chance of disease recurrence or spread, according to results released by Moderna and Merck.

可信度 72% 操纵 8% 中立
2026年八月20日
2 篇总计
Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer
Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer

Gizmodo • 08月20日 16:15

A Phase 3 trial showed that adding Moderna's personalized mRNA vaccine to Merck's Keytruda immunotherapy extended recurrence-free survival in high-risk melanoma patients.

可信度 72% 操纵 32% 中立
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next

Yahoo Finance • 08月20日 09:10

Moderna's stock fell 12% in pre-market trading following a 177% jump on news that its mRNA melanoma vaccine met primary endpoints in a Phase 3 trial, prompting mixed reactions from analysts.

可信度 72% 操纵 9% 中立
2026年八月19日
2 篇总计
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Ars Technica • 08月19日 16:53

A late-stage study of 1,137 melanoma patients showed that a personalized mRNA vaccine combined with Keytruda extended recurrence-free and distant metastasis-free survival, according to Moderna and Merck.

可信度 78% 操纵 12% 中立
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

NBC News • 08月19日 14:37

An mRNA-based personalized vaccine combined with Merck's Keytruda showed interim evidence of extending disease-free time for high-risk melanoma patients, according to a company release.

可信度 68% 操纵 12% 中立

相关事件